Stay Curious. Stay Connected.
MailNewsletters♡Donate Now
Sign up
*Password must be at least 8 characters and contain one uppercase letter, one lowercase letter, one number and one symbol.
Already have an account?
By submitting, you consent that you are at least 18 years of age and to receive information about MPR's or APMG entities' programs and offerings. The personally identifying information you provide will not be sold, shared, or used for purposes other than to communicate with you about MPR, APMG entities, and its sponsors. You may opt-out at any time clicking the unsubscribe link at the bottom of any email communication. View our Privacy Policy.
Sign in to your profile
Forgot Password?
New to MPR News?
Welcome back
to news
for you
Reset Password

Enter the username on file and we'll send you a code to reset your password.

Still require assistance or not sure what your User Name is?
Welcome back
to news
for you
Email Verification

A verification code has been emailed to

Still awaiting the code?

28 states settle Medicaid Rx overpayment

Go Deeper.

Create an account or log in to save stories.

Like this?

Thanks for liking this story! We have added it to a list of your favorite stories.

SAN FRANCISCO (AP) -- California and 28 other states have reached a $151 million settlement in a lawsuit alleging one of the country's largest drug wholesalers inflated prescription drug prices, costing the states' Medicaid programs millions in overpayments.

California Attorney General Kamala Harris announced the settlement with San Francisco-based McKesson Corp. on Friday. In California, Harris says the overpayments went on from 2001 through 2009.

California will receive about $23.5 million of the settlement amount.

The other states include New York, New Jersey, Pennsylvania, Colorado and Washington.

The settlement stems from a 2005 whistle-blower lawsuit that was filed under federal and states' false claims statutes. The federal government settled its portion of the lawsuit for more than $187 million in April 2012. A call to McKesson for comment was not immediately returned.